Ticker > Company >

Akums Drugs & Pharma share price

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS BSE: 544222 SECTOR: Pharmaceuticals & Drugs  29.15 K   27   13

578.50
-1.95 (-0.34%)
NSE: 04 Jul 04:08 PM

Price Summary

Today's High

₹ 583.2

Today's Low

₹ 568.55

52 Week High

₹ 1175.9

52 Week Low

₹ 405

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

9105.24 Cr.

Enterprise Value

8753.06 Cr.

No. of Shares

15.74 Cr.

P/E

56.55

P/B

3.95

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  146.52

CASH

356.12 Cr.

DEBT

3.93 Cr.

Promoter Holding

75.26 %

EPS (TTM)

₹  10.23

Sales Growth

-9.16%

ROE

13.15 %

ROCE

16.66%

Profit Growth

197.31 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.16%
3 Year4.12%
5 Year12.23%

Profit Growth

1 Year197.31%
3 Year34.29%
5 Year25.92%

ROE%

1 Year13.15%
3 Year-3.02%
5 Year-26.65%

ROCE %

1 Year16.66%
3 Year12.98%
5 Year-12.79%

Debt/Equity

0.0017

Price to Cash Flow

100.06

Interest Cover Ratio

14.5761

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 75.26 0.00
Dec 2024 75.26 0.00
Sep 2024 75.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 34.2890678418188% for the Past 3 years.
  • The company has significantly decreased its debt by 222.356 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 14.5761.
  • Company’s PEG ratio is 0.296211197078959.
  • The company has an efficient Cash Conversion Cycle of 24.1645 days.
  • Company has a healthy liquidity position with current ratio of 2.6937.
  • The company has a high promoter holding of 75.26%.

 Limitations

  • The company has shown a poor revenue growth of 4.12242934678213% for the Past 3 years.
  • Company has a poor ROE of -3.01553333333333% over the past 3 years.
  • The company has a low EBITDA margin of -2.21872% over the past 5 years.
  • The company is trading at a high PE of 56.55.
  • The company is trading at a high EV/EBITDA of 33.2788.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 317.28 328.35 337.41 328.75
Total Expenditure 273.59 285.28 303.38 311.03
Operating Profit 43.68 43.07 34.03 17.72
Other Income 26.18 32.12 33.84 32.05
Interest 6.21 4.18 2.29 2.63
Depreciation 9.38 9.39 10.68 10.09
Exceptional Items 0 0 0 0
Profit Before Tax 54.27 61.62 54.89 37.06
Tax 12.4 11.25 13.72 9.47
Profit After Tax 41.88 50.37 41.17 27.59
Adjusted EPS (Rs) 2.93 3.29 2.69 1.8

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 837.44 1162.06 1286.83 1444.12 1311.78
Total Expenditure 810.73 1524.1 1088.92 1570.78 1177.15
Operating Profit 26.7 -362.04 197.91 -126.66 134.63
Other Income 54.51 58.48 140.12 94.12 128.06
Interest 0.82 3.65 13.18 18.31 15.31
Depreciation 26.1 27.76 30 32.69 39.55
Exceptional Items -249.5 0 -144.53 -19.39 0
Profit Before Tax -195.2 -334.98 150.32 -102.93 207.84
Tax -49.77 46.8 24.89 62.52 46.84
Net Profit -145.43 -381.78 125.43 -165.45 161
Adjusted EPS (Rs.) -10.16 -26.69 8.77 -11.56 10.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 1.3 14.31 28.61 28.61 30.62
Total Reserves 565.75 171.23 282.89 115.27 2274.63
Borrowings 0 0 21.88 15.63 0
Other N/C liabilities 551.55 1092.56 1061.14 1434.19 70.36
Current liabilities 146 535.86 496.56 501.74 309.31
Total Liabilities 1264.6 1813.95 1891.07 2095.43 2684.91
Assets
Net Block 229.09 233.5 253.15 298.48 337.52
Capital WIP 1.26 0.52 16.13 8.57 53.71
Intangible WIP 0 0 0.12 0.09 3.02
Investments 130.45 141.39 139.16 138.92 366.01
Loans & Advances 508.57 858.15 937.52 1094.95 1071.11
Other N/C Assets 24.63 25.24 23.92 21.28 20.35
Current Assets 370.6 555.16 521.08 533.14 833.18
Total Assets 1264.6 1813.95 1891.07 2095.43 2684.91
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -195.2 -334.98 150.32 -102.93 207.84
Adjustment -19.27 -11.93 55.51 344.01 -57.03
Changes in Assets & Liabilities -28.45 99.58 -81.51 43.12 -10.94
Tax Paid -4.9 -7.19 -30.3 -36.29 -48.87
Operating Cash Flow 55.57 228.31 94.01 247.91 91
Investing Cash Flow -99.96 -297.96 -202.17 -165.44 -458.84
Financing Cash Flow 2.6 94.99 89.9 -20.74 375.38
Net Cash Flow -41.79 25.34 -18.26 61.72 7.53

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025%
promoters 75.26 75.26 75.26
akums master trust (sanje... - 40.79 40.79
lata jain 0.01 0.01 0.01
sandeep jain 17.24 17.24 17.24
sanjeev jain 17.23 17.23 17.23
akums master trust 40.79 - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025%
investors 24.74 24.74 24.74
franklin india smaller co... 1.71 2.12 3.31
llp 0.01 0.02 0.04
ruby qc investment holdin... 4.62 4.62 4.62
smallcap world fund, inc 2.15 2.15 1.69
akums employee benefits t... 2.73 2.73 -

Annual Reports

Title Link
Title Link
Annual Report 2025

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research IDBI Capital

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY25

Company News

Akums Drugs and Pharmaceuticals informs about AGM and annual report 24 Jun, 5:18 PM Akums Drugs and Pharmaceuticals informs about analyst meet 27 May, 2:43 PM Akums Drugs and Pharmaceuticals reports consolidated net profit of Rs 75.14 crore in Q4 27 May, 11:00 AM Akums Drugs & Pharma - Quaterly Results 26 May, 6:57 PM Akums Drugs & Pharma - Quaterly Results 26 May, 6:57 PM Akums Drugs and Pharmaceuticals informs about board meeting 19 May, 5:29 PM Akums Drugs and Pharmaceuticals informs about annual secretarial compliance report 17 May, 3:24 PM Akums Drugs and Pharmaceuticals informs about resignation of senior management personnel 26 Mar, 3:45 PM Akums Drugs secures patent for 'Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation' 15 Feb, 5:00 PM Akums Drugs and Pharmaceuticals informs about newspaper publication 15 Feb, 4:06 PM Akums Drugs and Pharmaceuticals reports 66% drop in Q3 consolidated net profit 7 Feb, 4:27 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs and Pharmaceuticals informs about analyst meet 3 Feb, 2:58 PM Akums Drugs and Pharmaceuticals informs about disclosure 22 Jan, 12:31 PM Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations 24 Dec, 3:28 PM Akums Drugs and Pharmaceuticals informs about updates 26 Nov, 5:11 PM Akums Drugs’ arm collaborates with Jagdale Industries 26 Nov, 3:42 PM Akums Drugs enters into exclusive Master Sales Agreement with Caregen 19 Nov, 2:51 PM Akums Drugs and Pharmaceuticals informs about press release 11 Nov, 2:38 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs and Pharmaceuticals enters into MoU with Government of Republic of Zambia 18 Oct, 2:27 PM Akums Drugs & Pharmaceuticals enters into license & distribution agreement with Triple Hair Inc 16 Oct, 3:45 PM Akums Drugs launches new product Famotidine, Calcium Carbonate and Magnesium Hydroxide 10 Oct, 9:22 AM Akums Drugs and Pharmaceuticals informs about closure of trading window 30 Sep, 12:33 PM Akums Drugs gets patent certificate from Government of India 13 Sep, 10:46 AM Akums Drugs and Pharmaceuticals informs about newspaper publication 26 Aug, 12:41 PM Akums Drugs & Pharmaceuticals - Quaterly Results 24 Aug, 5:30 PM Akums Drugs and Pharmaceuticals informs about earnings call 23 Aug, 2:49 PM Akums Drugs’ arm starts second production facility at Haridwar manufacturing unit 23 Aug, 11:00 AM Akums Drugs and Pharmaceuticals coming with IPO to raise upto Rs 1893.21 crore 27 Jul, 12:58 PM Akums Drugs and Pharmaceuticals gets SEBI’s nod for IPO 9 Jul, 2:40 PM Akums Drugs and Pharmaceuticals files DRHP with SEBI 14 Feb, 12:38 PM

Akums Drugs & Pharma Stock Price Analysis and Quick Research Report. Is Akums Drugs & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Akums Drugs & Pharma and its performance over the period of time. Akums Drugs & Pharma stock price today is Rs 578.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Akums Drugs & Pharma cash from the operating activity was Rs 91.002 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Akums Drugs & Pharma has a Debt to Equity ratio of 0.0017 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Akums Drugs & Pharma , the EPS growth was 190.9276 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Akums Drugs & Pharma has OPM of 10.2632750513804 % which is a bad sign for profitability.
     
  • ROE: Akums Drugs & Pharma have a average ROE of 13.1474 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Akums Drugs & Pharma is Rs 578.5. One can use valuation calculators of ticker to know if Akums Drugs & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Akums Drugs & Pharma
X